Philip Morris International

Philip Morris International Inc.
Type	Public
Traded as	NYSE: PM; S&P 500 component
Industry	Tobacco; Nicotine products
Founded	2008, by spin-off from Altria Group
Headquarters	Stamford, Connecticut, United States; operations centre in Lausanne, Switzerland
Key people	Jacek Olczak (Chief executive officer); Emmanuel Babeau (Chief financial officer)
Products	Cigarettes, heated tobacco, oral nicotine pouches, electronic cigarettes
Revenue	Approximately US$37.9 billion net of excise (2024)
Employees	Approximately 80,000
Website	pmi.com

Philip Morris International Inc. is a tobacco and nicotine company selling in more than 180 countries. Its best known brand is Marlboro, the largest-selling cigarette in the world, but since the final quarter of 2023 its largest single source of revenue has been Iqos, a heated tobacco system.

The company was created in 2008 when Altria Group separated its international tobacco operations from its American ones. The division is unusual and has consequences that persist: Philip Morris International owns the Marlboro trademark everywhere except the United States, where Altria owns it, and the two companies are legally separate and commercially distinct while selling products under the same names.

Philip Morris International is headquartered in Stamford, Connecticut, having moved from New York in 2014, with its principal operational centre in Lausanne, Switzerland. It reported net revenue excluding excise taxes of approximately US$37.9 billion for 2024 and earnings of approximately US$7.1 billion, and had a market capitalisation of about US$285 billion as of June 2025.

Since 2016 the company has publicly committed to what it calls a smoke-free future, stating an intention to stop selling cigarettes and to replace them with products it describes as presenting reduced risk. The commitment is genuine in that the company has spent more than US$12.5 billion on it and derived approximately 40 per cent of net revenue from such products by 2025, and it is contested in that the company sold approximately 617 billion cigarettes in 2024 and continues to market them in the countries where they sell best.

The World Health Organization and a large number of public health bodies decline to engage with the company, and its funding of the Foundation for a Smoke-Free World in 2017 was specifically criticised by the WHO as a conflict of interest.

History

Origins

Philip Morris International's history before 2008 is that of the international division of the Philip Morris Companies, which traces to a tobacconist opened by Philip Morris on Bond Street in London in 1847. The business was incorporated in the United States in 1902 and the American company became the dominant entity.

Marlboro, introduced in 1924 as a filtered cigarette marketed to women under the slogan "Mild as May", was repositioned in the 1950s. Filter cigarettes had acquired a feminine association at the moment when emerging evidence on lung cancer made filters commercially necessary, and the Leo Burnett agency's answer was the Marlboro Man, a cowboy, introduced in 1954. The campaign is generally regarded as the most effective in the history of advertising and took Marlboro from a marginal brand to the largest in the world within a decade.

The international business expanded aggressively from the 1960s, and grew further in the 1980s and 1990s as markets in Asia, Eastern Europe and the former Soviet Union opened, in several cases under trade pressure applied by the United States government on behalf of the industry.

The separation, 2008

Altria spun off Philip Morris International on 28 March 2008. The stated reasoning was that the two businesses faced entirely different circumstances: the American business was constrained by the 1998 Master Settlement Agreement, by Food and Drug Administration regulation from 2009 and by continuing litigation, while the international business faced growth markets and lighter regulation.

Critics, including public health organisations, argued that the separation freed the international business from the American litigation environment and from the disclosure obligations that litigation had produced, and allowed it to pursue markets where regulation was weakest without the constraint of American public opinion. The company's position was that the businesses were genuinely different and that the structure recognised it.

The trademark division means that Marlboro is sold by two unrelated companies. Philip Morris International owns the marks outside the United States and Altria within it, and the two have periodically been competitors, notably when Altria entered the vaping market through JUUL while PMI was developing Iqos.

Iqos and the smoke-free strategy, 2014 to 2026

Iqos, launched in Nagoya, Japan, and Milan in 2014, heats a tobacco stick to approximately 350 degrees Celsius rather than burning it at around 900, producing an aerosol containing nicotine and, according to the company's research, substantially lower levels of the harmful constituents generated by combustion.

Japan became the demonstration market. Iqos took a very large share of the Japanese tobacco market within five years, and Japanese cigarette sales declined at a rate that studies have attributed substantially to the substitution. The result was the strongest evidence available that a heated product could displace cigarettes at scale, and it was obtained in a country with unusual characteristics, including high smoking prevalence among men, strong regulation of vaping which left heated tobacco as the available alternative, and a population receptive to a device-based product.

In 2016 the company declared its intention to build a smoke-free future and applied to the United States Food and Drug Administration for authorisation of Iqos as a modified risk tobacco product. The FDA authorised marketing in 2019 and in July 2020 permitted a reduced exposure claim, that the system significantly reduces the body's exposure to harmful chemicals, while declining to authorise a reduced risk claim, on the ground that the evidence did not yet establish lower disease incidence. The distinction is important and is frequently elided in the company's marketing and in coverage of it.

American sales were then interrupted by patent litigation with British American Tobacco's Reynolds subsidiary, which resulted in an International Trade Commission exclusion order in 2021 and the withdrawal of Iqos from the American market. PMI reacquired the American commercialisation rights from Altria in 2022 for approximately US$2.7 billion and has been working toward re-entry.

The largest transaction of the period was the acquisition of Swedish Match in 2022 for approximately US$16 billion, completed after a contested process in which PMI raised its offer and settled for a majority stake before reaching full ownership. Swedish Match brought Zyn, an oral nicotine pouch, which has grown extremely rapidly in the United States, to the point of supply shortages in 2024, and which has become the company's principal growth product alongside Iqos.

The company also made an unsuccessful diversification into inhaled therapeutics, acquiring Vectura, a British respiratory drug delivery company, for approximately £1 billion in 2021, together with Fertin Pharma for DKK 5.1 billion and Otitopic. Vectura Fertin Pharma was formed in early 2022 and operated separately. The Vectura purchase produced substantial objection from respiratory clinicians and researchers, who argued that a tobacco company should not own a business supplying asthma inhalers, and a number of institutions refused to work with it. PMI sold Vectura in 2024, an outcome generally read as an acknowledgement that the strategy could not survive the reputational conflict.

In October 2024 the company announced the closure of all its German production sites, citing declining demand, and its Berlin manufacturing subsidiary began winding down.

Products

Cigarettes

Philip Morris International sold approximately 617 billion cigarettes in 2024. Its top five combustible brands accounted for 80 per cent of shipment volume.

Marlboro is the largest by a wide margin and is sold in most of the company's markets. L&M, Chesterfield, Parliament, Philip Morris and Bond Street cover the mid-price and value segments, with the last particularly significant in Eastern Europe and the former Soviet republics. Regional brands include Sampoerna in Indonesia, acquired in 2005 and among the largest tobacco businesses in the world by volume through kretek clove cigarettes, and Fortune in the Philippines.

Volumes have declined slowly and pricing has more than compensated, which is the defining economic characteristic of the industry: demand is inelastic because the product is addictive, so that price increases raise revenue even as units fall. This is why tobacco companies remain highly profitable in declining markets and why excise taxation is the most effective policy instrument available to governments.

Iqos

Iqos consists of a holder that heats a tobacco stick, branded Heets or Terea, and a charger. The system has been through several generations, and the Iluma version introduced in 2021 uses induction heating with a metallic element inside the stick rather than an external blade, which removed the cleaning requirement that had been the principal user complaint.

The company states that Iqos aerosol contains on average 90 to 95 per cent lower levels of harmful and potentially harmful constituents than cigarette smoke. Independent assessment has been mixed. Several studies have confirmed substantially lower levels of many combustion products; others have found some constituents at comparable or higher levels, have identified compounds not present in cigarette smoke, and have criticised the company's methodology, including the choice of comparators and the reliance on studies the company funded. The FDA's decision to permit a reduced exposure claim but not a reduced risk claim reflects this state of evidence.

Iqos is sold in more than 90 markets and has its strongest positions in Japan, Italy, and several Eastern European countries. It is prohibited in a number of jurisdictions, including India, Singapore and Australia for most purposes.

Oral nicotine

Zyn, acquired with Swedish Match, is a tobacco-free pouch placed under the lip, delivering nicotine without tobacco leaf, smoke or vapour. It has grown extremely rapidly in the United States and Scandinavia, where the related product snus has a long history and where population-level evidence from Sweden and Norway indicates substantially lower rates of tobacco-related disease than in countries where smoking predominates.

Zyn's growth has raised the same question as every nicotine product: whether it substitutes for cigarettes among existing smokers or recruits new users, particularly young people. American use among adolescents has risen, and regulators and legislators have examined the product's flavours and marketing. The FDA authorised Zyn in January 2025 on the ground that the benefit to adults switching outweighed the risk to youth, the first oral nicotine pouches to receive such authorisation.

Veev is the company's electronic cigarette, a category in which it has been less successful than in the other two.

Business and finances

Net revenue excluding excise taxes was approximately US$37.9 billion in 2024 with net earnings of approximately US$7.1 billion. Smoke-free products accounted for roughly 40 per cent of net revenue by 2025 and a higher proportion of gross profit, since their margins exceed those of cigarettes.

The company's markets are grouped into Europe, South and Southeast Asia and the Middle East, East Asia and Australia, the Americas, and Eastern Europe. Japan, Italy, Indonesia, Turkey, Germany and Poland are among the largest.

PMI pays a very large dividend, which has been raised annually, and its shares are held substantially by income investors. A significant number of institutional investors and pension funds exclude tobacco entirely on ethical grounds, which reduces the pool of buyers and has historically kept the valuation multiple below that of comparable consumer companies.

The company retained a substantial presence in Russia after the 2022 invasion of Ukraine. Its market share there was 30.1 per cent in 2019, and Ukraine's National Agency on Corruption Prevention has published figures for the corporate income tax it paid to the Russian budget in 2022 and has listed it as an international sponsor of war. PMI stated in 2022 that it intended to exit and has said since that it has been unable to do so on acceptable terms under Russian rules requiring state approval and heavy discounts for departing foreign owners.

Controversies

The public health position

The fundamental criticism of Philip Morris International is that it sells a product that kills a large proportion of the people who use it as intended, and that it continues to do so while presenting itself as a company working toward the elimination of that product.

Tobacco use causes approximately eight million deaths a year worldwide according to the World Health Organization. PMI's share of the global cigarette market outside China is the largest of any company.

The company's response is that adult smokers who will not quit are better served by switching, that the alternative to its providing reduced-risk products is that they continue smoking, and that a company with its manufacturing and distribution is better placed than anyone to accelerate the transition. The public health objection is threefold: that the company continues to market cigarettes hard in markets where the alternatives are not available or not affordable, particularly in Africa and parts of Asia; that the reduced-risk products recruit new nicotine users, including adolescents; and that the company's history of concealing what it knew about the harms of smoking makes its own research unusable as evidence.

That history is documented. Internal industry documents released through American litigation in the 1990s established that manufacturers understood the addictive properties of nicotine and the carcinogenicity of smoke decades before acknowledging them, funded research designed to manufacture doubt, and designed products to optimise nicotine delivery. Philip Morris International did not exist at the time, and its predecessor's conduct is the reason the World Health Organization Framework Convention on Tobacco Control contains Article 5.3, which obliges parties to protect public health policy from the commercial interests of the tobacco industry.

The Foundation for a Smoke-Free World

In 2017 PMI committed approximately US$80 million a year for twelve years to the Foundation for a Smoke-Free World, an ostensibly independent body led by the former World Health Organization official Derek Yach.

The WHO issued a statement identifying the conflict of interest involved in a tobacco company funding a purported health foundation, declined to partner with it, and invited governments and the public health community to do the same. Most academic institutions and journals refused funding from it, and several declined to publish work it had supported. The organisation was renamed Global Action to End Smoking in 2024 and stated that it would no longer accept PMI funding after the initial commitment ended.

Marketing and youth

PMI states that it markets only to adult smokers and nicotine users. Investigations have repeatedly found otherwise.

Reuters reported in 2019 on Iqos marketing in several countries using young social media influencers, including at least one under 21, which led PMI to suspend an influencer campaign. Campaigns in Japan, Italy, Israel and elsewhere have been examined by regulators. The 2026 French documentary Enfumés, by the investigative journalist Manon de Couët, who worked undercover in the industry, documented marketing strategies aimed at young people, including the use of pseudo-scientific claims and targeting of nightlife venues.

Zyn's flavours and its prominence on social media, where the term "zynfluencer" entered use, have attracted American congressional attention.

Sponsorship and advertising restrictions

Tobacco advertising is prohibited in most countries, and the industry's response has historically been to find channels the rules do not reach.

PMI's sponsorship of Ferrari in Formula One is the longest and most prominent. Direct Marlboro branding was removed under successive advertising bans, and from 2018 the car carried Mission Winnow branding, a PMI corporate initiative whose name and colour scheme authorities in several countries regarded as an attempt to circumvent the prohibition. It was removed from the car at the Australian and other Grands Prix after intervention by national authorities, and the branding was eventually withdrawn. The barcode-like design used on Ferrari cars in earlier seasons was likewise withdrawn in 2010 after complaints that it evoked the Marlboro packet.

The Philip Morris Arts Grant and the Philip Morris Collection, the latter established in 1973 and at one point the largest private corporate art collection in Australia, deposited with the National Gallery of Australia through a partnership with its director James Mollison, are examples of the cultural sponsorship the industry used extensively before it became reputationally untenable.

Litigation and regulation

PMI has challenged tobacco control measures through litigation and through investor-state dispute mechanisms.

It brought a claim against Uruguay under a Swiss bilateral investment treaty over large graphic health warnings and single presentation requirements, losing in 2016 and being ordered to pay costs, and against Australia over plain packaging under a Hong Kong treaty, using a corporate restructuring undertaken after the policy was announced, which the tribunal held in 2015 to be an abuse of process. Both cases were widely covered as examples of a company using trade law against public health policy, and both are credited with having slowed the adoption of plain packaging elsewhere by creating litigation risk for smaller governments.

The company has also litigated over flavour bans, display bans and, in the other direction, against counterfeiters and against competitors over heated tobacco patents, the last most significantly against British American Tobacco.

Corporate affairs

Jacek Olczak, a Polish executive who joined the company in 1993 and had been chief financial officer and chief operating officer, became chief executive in May 2021, succeeding André Calantzopoulos, who became executive chairman and who had been the principal architect of the Iqos strategy.

The company's legal headquarters is in Stamford, Connecticut, and its operations centre is in Lausanne, Switzerland, an arrangement that reflects both the international character of the business and the tax and regulatory environment. Its research and development centre, the Cube, is at Neuchâtel in Switzerland and employs several hundred scientists, and a second facility operates in Singapore.

PMI employs approximately 80,000 people, a large proportion in manufacturing and in leaf operations, and it contracts with a substantial number of tobacco farmers, principally in Brazil, Africa, Turkey and Asia, through a programme addressing child labour and agricultural practice that has been examined by Human Rights Watch and others and that has produced documented improvement and continuing findings of child labour in some supply chains.

The company reports on sustainability with unusual thoroughness for its industry, including a self-assessment against its own smoke-free targets, and this reporting has been both praised as transparency and criticised as an instrument for maintaining access to investors who apply environmental and social criteria.

The science of harm reduction

The dispute over Philip Morris International's strategy turns on a scientific question that is genuinely unsettled, and it is worth stating what is known.

What kills smokers is combustion, not nicotine. Nicotine is addictive and has cardiovascular effects, but the diseases caused by smoking, lung cancer, chronic obstructive pulmonary disease, cardiovascular disease and a long list of other cancers, are caused by the several thousand compounds produced when tobacco burns, including polycyclic aromatic hydrocarbons, nitrosamines, carbon monoxide, formaldehyde and benzene. This is the basis of the entire harm reduction argument and it is not seriously contested.

Products that do not burn produce far fewer of those compounds. Measurements of Iqos aerosol, by the company and by independent laboratories, consistently show large reductions in most measured toxicants, commonly in the range the company cites. Oral pouches produce none of them at all, since nothing is heated.

Reduced exposure is not the same as reduced risk. The relationship between dose and disease is not linear for every compound, some toxicants have no safe threshold, and a product may introduce constituents that cigarettes do not contain, which several studies of heated tobacco have reported. Establishing reduced disease incidence requires epidemiological data over decades, which does not yet exist for any of these products. This is why the FDA authorised an exposure claim and refused a risk claim.

The population question is separate from the individual one. Even if a product is substantially less harmful for an individual who switches completely, its net effect depends on who uses it. A product that moves existing smokers away from cigarettes reduces harm; a product that recruits people who would never have smoked, or that keeps people using nicotine who would have quit, or that is used alongside cigarettes rather than instead of them, does not. Dual use is common and is the most consistent finding in the literature.

The Swedish evidence is the strongest available. Sweden has the lowest rate of smoking in Europe and correspondingly low rates of lung cancer and other tobacco-related disease, and has had widespread use of snus for decades, particularly among men. Norway shows a similar pattern. The evidence is observational and confounded, and it is the closest thing to a population-level demonstration that substitution works.

The reasonable summary is that heated tobacco and oral nicotine are very probably less harmful than cigarettes for a person who switches completely, that how much less is unknown, that whether the products reduce harm at a population level depends on regulation and marketing rather than on chemistry, and that the company with the largest commercial interest in the answer is also the largest funder of research into it.

Markets

PMI's geographic position is the inverse of its predecessor's: it operates everywhere except the United States for cigarettes, and has been building an American business in smoke-free products.

Japan has been the decisive market for Iqos and remains its largest. Regulatory circumstances assisted: nicotine-containing vaping liquid is classified as a medicinal product and is effectively unavailable, so heated tobacco faced no competition from electronic cigarettes.

Italy was the first European launch market and has the highest European penetration. Other strong European markets include Poland, Greece, Portugal, Romania, the Czech Republic and Hungary. Germany has been weaker, and the company announced the closure of its German production in October 2024.

Indonesia is among the largest tobacco markets in the world, and PMI's Sampoerna subsidiary, acquired in 2005, is a leading producer of kretek, the clove cigarettes that dominate Indonesian consumption. The market has very high male smoking prevalence, weak advertising restrictions by international standards and a large informal sector.

Turkey, Egypt, the Philippines, Mexico and Brazil are substantial. India prohibits foreign direct investment in cigarette manufacturing and has banned heated tobacco and vaping, leaving PMI with a limited licensed presence.

Russia accounted for a large share of volume before 2022 and remains in the portfolio, as described above.

Africa is the region where growth in cigarette consumption is most likely, given population growth and weak tobacco control, and where the industry's conduct is most closely watched by public health organisations.

Timeline

1847 Philip Morris opens a tobacconist on Bond Street, London.
1924 Marlboro is introduced as a cigarette for women.
1954 The Marlboro Man campaign repositions the brand.
1990s Litigation in the United States forces disclosure of internal industry documents.
2005 Sampoerna is acquired in Indonesia.
2008 Philip Morris International is separated from Altria on 28 March.
2014 Iqos launches in Nagoya and Milan; the headquarters moves to New York and then Lausanne operations expand.
2015 The investment treaty claim against Australia over plain packaging is dismissed as an abuse of process.
2016 The claim against Uruguay is lost; the company announces its smoke-free commitment.
2017 The Foundation for a Smoke-Free World is funded and criticised by the World Health Organization.
2019 The FDA authorises Iqos marketing in the United States.
2020 The FDA permits a reduced exposure claim but not a reduced risk claim.
2021 Jacek Olczak becomes chief executive; Iqos is withdrawn from the United States after patent litigation; Vectura is acquired for about £1 billion.
2022 Swedish Match is acquired for approximately US$16 billion, bringing Zyn; the American Iqos rights are bought back from Altria.
2024 Vectura is sold; German production closes; approximately 617 billion cigarettes are sold.
2025 The FDA authorises Zyn; market capitalisation reaches approximately US$285 billion; smoke-free products approach 40 per cent of net revenue.
2026 The documentary Enfumés documents marketing practices directed at young people in France.

Assessment

Philip Morris International presents a question that does not resolve cleanly in either direction, which is why the argument about it has persisted for a decade without moving.

The company's transformation is measurable and is larger than that of any competitor. Approximately 40 per cent of its net revenue now comes from products that do not involve combustion, it has spent more than US$12.5 billion developing them, Iqos has displaced a substantial share of cigarette volume in Japan, and Zyn's growth in the United States is occurring principally among adults. If the objective of tobacco control is to reduce the number of people inhaling combustion products, the company has contributed more to that objective in ten years than most policy interventions.

The same company sold 617 billion cigarettes in 2024, markets them hardest where alternatives are least available, retained a Russian business through a war, has used investment treaties against public health legislation in Uruguay and Australia, funded a purported health foundation the World Health Organization refused to deal with, and has been repeatedly found marketing in ways that reach young people. The transformation is proceeding at the pace that maximises revenue, which is not the pace that would minimise harm, and the company retains every commercial reason to continue selling cigarettes until something replaces the profit.

Both descriptions are accurate and they are not in tension, because they describe the same commercial logic. A company whose existing product is declining will invest in a replacement, and will do so while extracting the maximum from the existing product, and will describe the investment in the terms most favourable to its regulatory position. The public health question is not whether PMI's stated commitment is sincere, which is unanswerable and largely irrelevant, but whether the products it is transitioning toward are sufficiently less harmful, and whether the transition can be accelerated by regulation faster than the company would choose.

On the first, the evidence supports substantially reduced exposure and does not yet establish reduced disease, which is a distinction that will take decades to settle and that the company's marketing does not observe carefully.

On the second, the instruments available, excise differentials favouring lower-risk products, restrictions on flavours and marketing that reach young people, and the Article 5.3 obligation to keep the industry out of policy, point in different directions, which is why tobacco control has been more divided over heated tobacco and nicotine pouches than over anything since the introduction of filters.